Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Shangshi Jietong Gao (SJG) is a Traditional Chinese Medicine (TCM) herbal patch indicated for the short-term management of pain associated with knee osteoarthritis and other joint conditions. It is formulated based on TCM principles to address "cold dampness" and "blood stasis" syndromes, which are characterized by pain, stiffness, and malfunction in the joints. The patch contains 17 active herbal ingredients, including raw Rhizoma Arisaematis (Sheng Tiannanxing), raw Radix Aconiti (Sheng Chuanwu), and Rhizoma Curcuma Longae (Jianghuang), which are believed to provide analgesic and anti-inflammatory effects. SJG is manufactured by Changzhou Shenghui Pharmaceutical and holds China State Food and Drug Administration (SFDA) approval (no. Z32021099). Clinical trials have evaluated its efficacy using measures such as the Visual Analogue Scale (VAS) and the WOMAC index, demonstrating its utility as a topical therapy for symptomatic relief in osteoarthritis patients.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on shangshi jietong gao.